James Douglas Hunter

Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.